PredicTx Health

Based in Australia, PredicTx Health specializes in precision oncology, leveraging innovative body analysis technology to optimize chemotherapy dosing for enhanced patient care. PredicTx Health focuses on providing personalized oncology solutions through advanced body analysis. Founded in 2025 in Melbourne, Australia, the company has completed 2 deals as of October 17, 2025. In October 2025, PredicTx Health received an undisclosed amount of grant  funding  from Australia's Economic Accelerator and Victorian Department of Health.

The round was part of a larger USD 1. 6 million angel and grant funding. The company has not undergone any significant operational pivots or changes since its inception. PredicTx specializes in precision oncology care, primarily through its innovative platform that leverages CT-based body analysis to enhance chemotherapy dosing accuracy.

The core functionality of their service involves analyzing patient scans to segment muscle, fat, bone, and tumor volumes, allowing for the creation of detailed body composition profiles. This data is processed through a machine learning model designed to predict optimal chemotherapy dosages tailored to individual patients before their first treatment cycle. The primary end users of PredicTx's offerings include oncologists, healthcare institutions, and cancer patients across various geographical markets, including North America, Europe, and Australia. The company aims to address significant issues in current chemotherapy protocols that often overlook individual metabolic differences, resulting in incorrect dosing and treatment complications.

PredicTx generates revenue through a B2B model, primarily focusing on partnerships with healthcare institutions and oncology clinics that utilize their body analysis platform. The transactional structure typically involves subscription agreements for access to the platform, which includes ongoing support and updates based on the latest research in personalized medicine. Clients pay for services that include detailed body composition analysis and the optimized chemotherapy dosing recommendations. While specific pricing details for their services are not disclosed, the company’s offerings are designed to integrate seamlessly into existing oncology workflows, ensuring that healthcare providers can implement precision dosing strategies effectively.

This integration enhances patient outcomes by reducing toxicity and treatment dropouts, serving as a compelling value proposition in the oncology care market. In October 2025, PredicTx Health raised USD 1. 6 mn in pre-seed funding from Tanarra Capital. The company will use the funding to develop a platform that supports personalized chemotherapy dosing using body composition data.

Future initiatives include launching new products aimed at improving treatment personalization and expanding into North America and Europe by the end of 2026.